Agila, Pfenex sign biosimilar joint venture deal

04/17/2013 | Genetic Engineering & Biotechnology News

Pfenex and Agila Biotech agreed to develop, manufacture and market six biosimilars as part of a joint venture. Pfenex will combine its strain engineering and process development know-how with Agila's biologics production and clinical development expertise. The venture's lead product will be interferon beta-1b, a biosimilar version of multiple sclerosis treatment Betaseron.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD